-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Announces Investigation into iRhythm Technologies, Inc. (IRTC)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) and certain of its officers and directors issued false and/or misleading statements and/or failed to disclose information pertinent to investors in violation of federal securities laws. If you purchased or otherwise own iRhythm securities, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312 for more information.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services.

On May 30, 2023, iRhythm disclosed that on May 25, 2023, it had received a warning letter from the U.S. Food and Drug Administration (“FDA”), alleging non-conformities to regulations for medical devices, including medical device reporting requirements, related to the Company’s Zio AT System and medical device quality system requirements.

On this news, iRhythm's stock price fell $7.41 per share, or 6.09%, to close at $114.27 per share on May 31, 2023.

What You Can Do – CLICK HERE

If you purchased or otherwise own iRhythm securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Scott+Scott Attorneys at Law LLP

NASDAQ:IRTC

Release Versions

Contacts

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Announces Preliminary Approval of Class Action Settlements in SafeMoon Class Action Litigation

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP, as Lead Counsel for investors in the SafeMoon securities class action, announced a proposed $12 million settlement resolving claims against Debtor Defendant SafeMoon US, LLC. The settlement follows mediation before Chief Magistrate Judge Dustin B. Pead of the District of Utah, capping litigation that began in February 2022. That litigation included related criminal charges against former SafeMoon CEO Braden John Karony, who was convict...

THE ENSIGN GROUP, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates The Ensign Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ENSG

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of The Ensign Group, Inc. (NASDAQ: ENSG) failed to manage The Ensign Group in an acceptable manner, breaching their fiduciary duties to Ensign Group, and whether Ensign Group and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On June 11, 2026, Muddy Waters Resear...

FIRST BANCORP. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates First BanCorp.’s Directors and Officers for Breach of Fiduciary Duties – FBP

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of First BanCorp. (NYSE: FBP) failed to manage First BanCorp in an acceptable manner, breaching their fiduciary duties to First BanCorp., and whether First BanCorp. and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On June 24, 2026, one of Jeffrey Epstein’s sex...
Back to Newsroom